



SCOHIA PHARMA Inc. SEEDSUPPLY Inc. November 25, 2019

SCOHIA and SEEDSUPPLY Announce Research Collaboration Agreement

SCOHIA PHARMA, Inc ("SCOHIA") and SEEDSUPPLY Inc. ("SEEDSUPPLY") announce that the two companies have entered into a research collaboration agreement to conduct exploratory research on new drug candidates in disease areas with high unmet needs.

Under this agreement, SCOHIA and SEEDSUPPLY aim to create innovative drug candidates for maximum 20 drug discovery targets during the period of 2 years by combining the drug discovery know-how of SCOHIA and the Binder Selection Technology of SEEDSUPPLY. SCOHIA will acquire the worldwide exclusive right to commercialize the drug candidates derived from lead compounds obtained through this research collaboration.

The Binder Selection Technology is SEEDSUPPLY's proprietary technology for high-throughput screening by which more accurate and rapid screening can be performed for a numbers of drug discovery targets including the targets that could not be handled by the existing screening technologies. SCOHIA, with talented R&D team who has robust track record in R&D of multiple marketed drugs, has a high drug discovery capability covering from preclinical to clinical stages. The two companies will contribute to people's health in the world by rapidly discovering new drug candidates and creating new innovative medicines by advantages of both companies.

Contact information:

info@scohia.com (SCOHIA PHARMA)

info.ss@seedsupply.co.jp (SEEDSUPPLY)





[About SCOHIA PHARMA Inc.]

SCOHIA, a drug discovery bio startup, carries out the R&D of drugs primarily in the field of lifestyle-related diseases such as cardiovascular, metabolism, and kidney diseases. The company has strength in rich product portfolio in pre-clinical and clinical stages and R&D team who has robust track record and experience in all the processes of R&D of including drug discovery, pre-clinical evaluation and clinical development. Please visit the website https://www.scohia.com/ for more information about SCOHIA.

[About SEEDSUPPLY Inc.]

SEEDSUPPLY, a technological startup, provides drug discovery support services using its proprietary analysis technology for compound–target interactions. The company contributes to drug discovery research by identifying solid binding compounds for all drug discovery targets including soluble proteins, membrane proteins, and RNA chains. Please visit the website http://www.seedsupply.co.jp/ for more information about SEEDSUPPLY.